Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Oct 28, 2014; 20(40): 14733-14746
Published online Oct 28, 2014. doi: 10.3748/wjg.v20.i40.14733
Published online Oct 28, 2014. doi: 10.3748/wjg.v20.i40.14733
Table 3 Major adjuvant chemoradiotherapy trials in pancreatic cancer
| Final analysis | Survival (95%CI) | Disease-free survival (DFS) (95%CI) | |||||||||
| Year published | Author/group | Treatment arms (n) | T3 | N+ | R0 | Median survival (mo) | 2-yr survival | 3-yr survival | 5-yr survival | Median DFS (mo) | 2-yr DFS |
| 1985 | GITSG | CRT (21) | 37 | 28 | 100 | 21 | 43% (0.25%-0.63%) | - | - | - | - |
| Surgery alone (22) | 10.9 | 18% (0.08%-0.36%) | |||||||||
| 1999 | EORTC | 5-FU/RT (104) | 21 | 46 | 77 | 24.5 | 51% (41%-61%) | - | 28% (17%-39%) | 17.4 | 38% (28%-48%) |
| Surgery alone (103) | 19 (log rank P = 0.208) | 41% (31%-51%) | 22% (12%-32%) | 16 (P = 0.643) | 37% (27%-47%) (P = 0.643) | ||||||
| 5-FU/RT (60) | 0 | 51 | NA | 17.1 | 37% (24%-50%) | - | 20% (5%-35%) | - | - | ||
| Surgery alone (54) | 12.6 (log rank P = 0.099) | 23% (11%-35%) | 10% (0%-20%) | ||||||||
| 2001 | ESPAC-1 (all patients) | CRT +/- 5-FU/folinic acid (175) | NA | 56 | 82 | 15.5 (13.5-17.4) | - | - | - | - | - |
| No CRT +/- 5-FU/folinic acid (178) | 16.1 (13.1-20.1) (HR = 1.18, 0.9-1.55, P = 0.24) | ||||||||||
| ESPAC-1 (2 × 2 design only) | CRT +/- 5-FU/folinic acid (142) | NA | NA | NA | 15.8 (13.5-19.4) | - | - | - | - | - | |
| No CRT +/- 5-FU/folinic acid (143) | 17.8 (14-23.6) (HR = 1.3, 0.96-1.77, P = 0.09) | ||||||||||
| 2004 | ESPAC-1 (2 × 2 final analysis) | CRT +/- 5-FU/folinic acid (145) | NA | 53 | 82 | 15.9 (13.7-19.9) | 29% | - | 10% | - | - |
| No CRT +/- 5-FU/folinic acid (144) | 17.9 (14.8-23.6) (HR = 1.28, 0.99-1.66, P = 0.05) | 41% | 20% | ||||||||
| ESPAC-1 (Individual Treatment Groups) | 5-FU/folinic acid (75) | 21.6 (13.5-27.3) | 29% | ||||||||
| CRT + 5-FU/folinic acid (72) | 19.9 (14.2-22.5) | - | - | 13% | - | - | |||||
| Observation (69) | 16.9 (12.3-24.8) | 11% | |||||||||
| CRT (73) | 13.9 (12.2-17.3) | 7% | |||||||||
| 2006 | RTOG 97-04 | CRT + 5-FU (230) | 75 | 66 | 66 | No significant difference | - | - | - | - | - |
| CRT + gemcitabine (221) | |||||||||||
| CRT + 5-FU (201) | NA | NA | NA | 16.9 | - | 22% | - | - | - | ||
| CRT + gemcitabine (187) | 20.5 (HR = 0.82, 0.65-1.03, P = 0.09) | 31% | |||||||||
| 2011 | RTOG 97-04 (5-yr analysis) | CRT + 5-FU (230) | 75 | 66 | 66 | No significant difference | 35% | 23% | 19% | n/s | - |
| CRT + gemcitabine (221) | HR = 0.933, 0.76-1.145, P = 0.51 | 40% | 27% | 19% | |||||||
| CRT + 5-FU (201) | NA | NA | NA | 17.1 | 34% | 21% | 18% (13%-24%) | - | - | ||
| CRT + gemcitabine (187) | 20.5 | 42% | 28% | 22% | |||||||
| 2012 | CapRI (Schmidt) | 5-FU/cisplatin/interferon α-2b → RT → 5-FU (53) | 97 | 79 | 61 | 32.1 (22.8-42.2) | - | - | - | 15.2 (10.3-24.8) | - |
| 5-FU/folinic acid (57) | 28.5 (19.5-38.6) (HR = 1.2, 0.49-2.95, P = 0.49) | 11.5 (9.8-17.6) (P = 0.61) | |||||||||
- Citation: Jones OP, Melling JD, Ghaneh P. Adjuvant therapy in pancreatic cancer. World J Gastroenterol 2014; 20(40): 14733-14746
- URL: https://www.wjgnet.com/1007-9327/full/v20/i40/14733.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i40.14733